This finding either supports the significance of the systemic effects of CDK4/6 inhibitors on the host immune compartment (T-cell memory) or that CDK4/6 inhibitors impinge on other features of tumor biology distinct from RB activation50,51. This evidence concerns the gene CDK4 and neoplasm.